Screening of NASH in Oupatients Followed in Various Hospital Specialty Clinics at the University Hospital of Strasbourg (NASH-SPE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The aim of the present study is to assess, by using a simple algorithm combining FIB-4 and Fibroscan, the prevalence of NASH with advanced fibrosis in outpatients followed in various hospital specialty clinics other than hepato/gastroenterology and to examine risk factors associated with this condition. The prevalence of NASH will be investigated among 6 cohorts of outpatients followed in different hospital specialty clinics at Hôpitaux Universitaires de Strasbourg.
Estimated prevalence of NASH with advanced fibrosis among several hospital specialty clinics [ Time Frame: 3 months ]
To assess the estimated prevalence of NASH with advanced fibrosis among several hospital specialty clinics by using the combination of FIB4 and fibroscan in outpatients at risk of NAFLD with no excessive alcohol consumption or viral hepatitis followed in endocrinology, cardiology, internal medicine, rheumatology, nephrology and infectious disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Outpatients followed at specialty clinics in HUS and at risk of NAFLD: with at least one metabolic risk factor (overweight, diabetes mellitus, hypertension, hypertriglyceridemia) and/or elevated transaminases and/or liver steatosis on US.
age ≥ 18 years
outpatients followed at specialty clinics in HUS and at risk of NAFLD: with at least one metabolic risk factor (overweight, diabetes mellitus, hypertension, hypertriglyceridemia) and/or elevated transaminases and/or liver steatosis on US.
endocrinology cohort : type 2 diabetes patients
infectious disease cohort : HIV positive patients
rheumatology cohort : patients with psoriasis, gout or rheumatoid arthritis
nephrology cohort : patients with chronic kidney disease such as diabetic nephropathy or hypertensive nephropathy, including those receiving hemodialysis.
cardiology cohorts: patients with history of angina, myocardial infarction, stroke or arteritis of lower limbs.
internal medicine cohort: patients with auto immune systemic diseases such as lupus, sclerosis or rheumatoid arthritis.
subjects who have given their informed consent
Subjects affiliated to a social security system
alcohol consumption > 30g/d in male or > 20g/d in female in the past 6 months
history of chronic viral hepatitis
history of liver auto immune disease, genetic hemochromatosis, Wilson disease
biliary disease, bile duct obstruction
drug-induced liver injury
secondary liver cancer or other active cancer
use of medications associated with secondary NAFLD (corticosteroids, tamoxifen, amiodarone, methotrexate).
congestive heart failure
no information could be given to the patient (subject faces emergency situation, comprehension difficulties, etc.)